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Background: Signs of an inflammatory process have been described in major 
depression.
Methods: In a double-blind, randomized study of celecoxib or placebo add-on to rebox-
etine in 40 depressed patients, celecoxib treatment has beneficial effects. In order to 
evaluate the tryptophan/kynurenine metabolism and to identify predictors for remission, 
tryptophan (TRP), kynurenine (KYN), kynurenic acid (KYNA), and quinolinic acid (QUIN) 
were estimated in the serum of 32 patients before and after treatment and in a group of 
20 healthy controls.
results: KYN levels were significantly lower in patients (p =  0.008), and the QUIN/
KYN ratios were significantly higher (p = 0.028). At baseline, the higher KYN/TRP ratio 
was predictive for remission during celecoxib add-on treatment (p = 0.04) as well as for 
remission in the overall patient group (p = 0.01). In the placebo group, remitters showed 
a higher KYNA/QUIN ratio (p =  0.032). In the overall group, remitters showed lower 
KYNA/KYN (p = 0.035) and QUIN/KYN (p = 0.011) ratios. The lower the formation of 
downstream metabolites, especially QUIN, the better the treatment outcome.
conclusion: The high KYN/TRP ratio predicted remission after treatment with celecoxib 
in this small sample of depressed patients. Eventually, the KYN/TRP ratio might be a 
marker for those patients, which benefit from an additional anti-inflammatory treatment.
Keywords: depression, cyclooxygenase-2, celecoxib, kynurenines, remission
inTrODUcTiOn
Activation of the inflammatory response system in major depression (MD) is well documented 
(1–5). Recent meta-analyses clearly showed elevated interleukin-6 (IL-6) levels in patients with 
MD (6–9).
However, the findings of these meta-analyses differed regarding levels of the inflammatory mark-
ers C-reactive protein (CRP), IL-1, IL-1RA, and TNF-α, with more hints toward increased CRP levels 
and no association for TNF-α and IL-1 in depression (8). In general, the inflammatory response 
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system appears to be activated, but the levels of the different 
markers vary across studies.
Prostaglandin E2 (PGE2) is an important mediator of inflam-
mation (10). Increased PGE2 in the saliva, serum, and cerebro-
spinal fluid of depressed patients has been described previously 
(11–14). The enzyme cyclooxygenase-2 (COX-2) is involved in 
the function of PGE2 in the inflammatory pathway. The COX-2 
inhibitor celecoxib, an add-on to different antidepressants, has 
demonstrated beneficial effects in the treatment of depression 
(15, 16). Although not all patients who received celecoxib add-
on remitted, celecoxib showed significant advantages over the 
placebo add-on. However, side effects, including cardiovascular 
effects, have been observed during the use of COX-2 inhibitors, 
particularly in long-term treatment. With these specific side 
effects of celecoxib, screening and monitoring for cardiovascular 
risk factors and events is important, when treating MD with 
COX-2 inhibitors. Also, a recent meta-analysis with a total of 
150 patients has shown that the adjunctive celecoxib group had 
better remission and response rates than the placebo group (17).
Taken this together, it would be desirable to predict remission 
to the therapy with celecoxib. Predictive markers of the immune 
system for antidepressant therapy response have been described 
before. Decreased IL-6 levels were predictive for response to 
antidepressant pharmacotherapy (18, 19). A very recent study 
identified increased cytotoxic T cells and decreased natural killer 
cells as possible predictors for treatment response in MD (20).
Additionally, a meta-analysis showed that persistently elevated 
TNFα was associated with prospectively determined treatment 
resistance for depressed patients (21). Products of the tryptophan/
kynurenine metabolism, however, have not yet been studied under 
the aspect of antidepressant therapy, although they are induced 
by an enhanced inflammatory response and proposed to be 
involved in the pathophysiology of depression (22, 23). Enzymes 
of the tryptophan–kynurenine metabolism are regulated by pro-
inflammatory cytokines and prostaglandin E2 as a coactivator, 
in particular the indoleamine 2,3-dioxygenase (IDO), which 
metabolizes tryptophan to kynurenine. Moreover, metabolites of 
tryptophan metabolism are plausible biomarkers for depression 
since the biological ranges are fairly narrow, the detection rate 
in blood is good, and they discriminate satisfactorily between 
depressed patients and controls (24). The precise degradation of 
tryptophan leads to different neurotransmitters that are excito-
toxic (25) or N-methyl-d-aspartate receptor antagonists (26). The 
hypothesis of the current study is that the measurement of the 
way tryptophan is metabolized could help to identify remitters 
already before the onset of treatment. Therefore, in this 6-week 
study, we evaluated key tryptophan metabolites to investigate 
whether they predict the outcome of treatment with celecoxib as 
an add-on to an antidepressant.
MaTerials anD MeThODs
Patients and controls
In total, 60 subjects participated in this study. Of these, 40 
participants were patients (20 males and 20 females) aged 
between 23 and 63  years. All patients were diagnosed with 
MD according to DSM IV (DSM IV: 296.2 × single depressive 
episode or 296.3 × recurrent depressive episode) and needed to 
have a 17-item Hamilton Depression Scale (HAMD-17) score 
of at least 15 (range for included depressed patients was from 
15 to 38). Patients suffering from psychotic depression or also 
other inflammatory diseases (e.g., multiple sclerosis, rheuma-
toid arthritis, and inflammatory bowel disease) were excluded. 
Current intake of NSAID for any reason (including pain) was an 
exclusion criterion. Also, a history of substance or alcohol abuse/
dependence and severe physical illnesses were exclusion criteria. 
Each patient was included after written informed consent. The 
study was examined and approved by the ethics committee of 
the medical faculty of the University of Munich in accordance 
with the Declaration of Helsinki 1975, revised Hong Kong 1989. 
The depressed patients were study participants of a double-blind 
randomized, placebo-controlled, and prospective parallel group 
trial of celecoxib add-on to reboxetine. After a wash-out period 
(or without, in case patients were not medicated) of 3–7  days 
(according to the prior drug used; no patient had prior fluoxetine 
treatment), the patients were randomized to either celecoxib or 
placebo. The treatment period lasted 42 days (6 weeks). Patients 
were permitted to take benzodiazepines if needed for bridg-
ing the gap until reboxetine showed its effects. The results of 
the clinical parameters were reported in detail elsewhere (16). 
Briefly, 20 of the 40 patients (12 males, 8 females) were allocated 
to treatment with celecoxib as an add-on to reboxetine and 20 (8 
males, 12 females) to placebo add-on to reboxetine. The dose of 
reboxetine was flexible and ranged from 4 to 10 mg/day, accord-
ing to the clinical needs. Celecoxib was administered at a dose 
of 400 mg/day.
The baseline mean scores on the HAMD-17 were 25.4 (SD 
4.0) in the celecoxib group and 24.6 (SD 5.9) in the reboxetine 
plus placebo group. After exclusion of drop-outs and patients 
whose blood samples were no longer available from the baseline 
sample collection, a total of 32 subjects (18 in the celecoxib group 
and 14 in the placebo group; age 44.6 ±  11.6 years; age range: 
25–65 years; 16 females, 16 males) were included in the study. 
Remitters were defined as patients whose scores on the HAMD-
17 had decreased to 7 or less by the end of the study. Six of 18 
patients in the celecoxib group and 3 of 14 in the placebo group 
were remitters. The relatively high drop-out rate (in particular in 
the reboxetine plus placebo group) might partly be explained by 
the limited antidepressant effects of reboxetine and partly by the 
side effects of reboxetine (16).
A total of 20 healthy, age-matched controls (age 40.0 ± 10.4 years; 
age range: 24–60  years; 5 females, 15 males) were recruited to 
allow comparison of the tryptophan metabolism parameters. 
A non-structured clinical interview was used to exclude par-
ticipants with a personal or familial history of psychiatric illness, 
diagnosed autoimmune disease, or substance or alcohol abuse. 
These interviews were performed by an experienced psychiatrist. 
The healthy controls were free of chronic or acute physical illness 
associated with altered states of immunity and showed normal 
blood chemistry values (this included normal ranges of complete 
blood count, liver and renal function, and thyroid hormones). 
Please see Table 1 for characteristics of study participants.
The study was approved in accordance with the ethical stand-
ards of the responsible committee on human experimentation 
TaBle 1 | characteristics of study participants.
Patient’s 
characteristics
celecoxib group 
(n = 18)
Placebo group 
(n = 14)
controls 
(n = 20)
Sex 11 males, 7 females 5 males, 9 females 15 males, 
5 females
Mean age (years) 44.6 ± 11.5 43.9 ± 13.3 40.0 ± 10.4
Remitters 6 with HAMD-17 < 7 3 with HAMD-17 < 7
Mean 
benzodiazepine 
dose
2.4 ± 3.0 mg/day 2.7 ± 3.1 mg/day
FigUre 1 | comparison of the KYn/TrP ratio at baseline (KYn/TrP V0) between remitters (n = 6) and non-remitters (n = 12) in the celecoxib add-on 
group.
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[medical faculty of the Ludwig Maximilian University (LMU)] or 
with the Declaration of Helsinki 1975, revised Hong Kong 1989. 
Written informed consent was obtained from each participant.
Biochemical analyses
Kynurenines were analyzed in serum obtained from fasting, early 
morning venous blood samples.
Tryptophan (TRP), kynurenine (KYN), and kynurenic 
acid (KYNA) were analyzed at the Psychoneuroimmunology 
Laboratory of the Department of Psychiatry and Psychotherapy, 
LMU, Munich, with high-performance liquid chromatography 
(HPLC) according to the method of Oades et al. (27). Analytes 
were extracted from the samples and calibrators/controls by using 
Waters Oasis MCX 1 cc (30 mg) extraction cartridges. The eluent 
was evaporated to dryness under nitrogen and reconstituted with 
150  µl 0.1  M PBS. Reconstituted samples/calibrators/controls 
were analyzed with HPLC with 250 mm × 4 mm Supersphere 60 
RP-select B, C8 column (Merck, Darmstadt, Germany). TRP (lex: 
300 nm; lem: 350 nm) was measured by fluorescence detection, 
and KYN (365  nm) and KA (330  nm) were measured by UV 
detection.
Serum quinolinic acid (QUIN) was analyzed at the 
Laboratory of Immunology and Transfusion Medicine at the 
University of Greifswald on a Hewlett-Packard model 5988 
quadrupole mass spectrometer operated in the electron capture 
negative chemical ionization mode with methane as the reagent 
gas (0.5 Torr). Sample extraction was performed according to 
Morrison et  al. (28).
The coefficient of variation of the above analyses ranged from 7 
to 10. Patient and control samples were analyzed in random order, 
and the technical assistants who analyzed the samples and read 
the chromatograms were blind to the diagnoses and treatment 
groups. Finally, in order to estimate TRP degradation, the KYN 
to TRP ratio (KYN/TRP) was calculated, which is an indirect 
marker for the activity of the enzyme indoleamine 2,3-dioxyge-
nase. For the further degradation of KYN, the ratios KYNA/KYN 
and QUIN/KYN were calculated, as these ratios provide insights 
of the accumulation of neuroactive substrates.
FigUre 2 | comparison of the KYna/QUin ratio at baseline (KYna/QUin V0) between remitters (n = 3) and non-remitters (n = 11) from the placebo group.
4
Krause et al. Tryptophan Predicts Remission in Depression
Frontiers in Psychiatry | www.frontiersin.org February 2017 | Volume 8 | Article 16
statistical analyses
Student’s t-test was used to compare normally distributed data 
between patients and controls and between different subgroups. 
Linear regression analysis was performed to analyze the effect of 
the parameters of TRP/KYN metabolism on remission to treat-
ment (HAMD ≤  7) in treatment subgroups, and multivariate 
analysis controlling for age and gender was performed to analyze 
the effect in the overall group. SPSS version 18.0 was used, and 
p < 0.05 was considered significant.
resUlTs
Patients vs controls
Serum KYN levels were significantly lower (1.78  ±  0.35 vs 
2.04 ±  0.35  µg/ml; t = −2.78, p =  0.008) in patients (n =  32) 
than in controls (n =  20), but QUIN/KYN ratios were signifi-
cantly higher (0.17 ± 0.05 vs 0.14 ± 0.03; t = −2.28, p = 0.028). 
Tryptophan did not differ significantly between the two groups. 
Serum KYNA levels showed a trend toward being lower in the 
patient group (0.311 ± 0.054 vs 0.347 ± 0.087 ng/ml; t = −1.808, 
p = 0.077).
celecoxib vs Placebo
Tryptophan metabolites did not differ significantly between the 
celecoxib (n = 18) and control groups (n = 14) at baseline or after 
6 weeks of treatment.
remitters vs non-remitters of the 
Depressed Patients
In the celecoxib group (add-on to reboxetine), remitters (n = 6) 
showed a higher KYN/TRP ratio (11.76 ± 2.07 vs 9.54 ± 1.68; 
t = 2.2, p = 0.034) at baseline (Figure 1). In the linear regression 
analysis, the baseline elevated KYN/TRP ratio was predictive for 
remission to celecoxib add-on treatment in terms of the percent-
age of patients showing a decrease in HAMD score to 7 or less at 
the end of the study (B = 0.03, CI = 0.001–0.059, p = 0.04).
In the placebo group (add-on to reboxetine), remitters (n = 3) 
showed a higher KYNA/QUIN ratio (1.36 ± 0.059 vs 1.07 ± 0.162; 
t = −2.25, p = 0.032).
In the overall group (celecoxib and placebo add-on to 
reboxetine), remitters (n = 9) showed a higher KYN/TRP ratio 
(11.51 ± 1.81 vs 9.31 ± 1.99; t = −2.72, p = 0.011) (Figure 2) 
and lower KYNA/KYN (0.163 ± 0.017 vs 0.19 ± 0.051; t = −2.22, 
p = 0.035) (Figure 3) and lower QUIN/KYN (0.139 ± 0.022 vs 
0.179 ± 0.057; t = −2.74, p = 0.011) ratios. When age and gender 
were controlled for, higher KYN/TRP was predictive for remission 
to antidepressant treatment with or without celecoxib add-on in 
terms of reduction of HAMD score to 7 or below (B = 33.012, 
F = 10.312, p = 0.004).
DiscUssiOn
Our results show that initial serum kynurenine levels predict 
remission after add-on treatment with the COX-2 inhibitor 
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FigUre 3 | comparison of QUin/KYn ratio at baseline (QUin/KYn V0) between remitters (n = 9) and non-remitters (n = 23) from the overall group of 
patients with major depression.
celecoxib. More precisely, the higher KYN/TRP ratio at baseline 
predicted both remission in the celecoxib add-on group and in 
the whole (reboxetine) group. The KYN/TRP ratio indicates the 
activity of the enzymes tryptophan 2,3-dioxygenase (TDO) and 
indoleamine 2,3-dioxygenase (IDO), which reflect a response of 
the inflammatory system. Circulating monocytes have already 
been identified to overexpress inflammatory genes in depressed 
patients (6). Therefore, we conclude that the activity of the inflam-
matory response system predicts the outcome of treatment with 
the anti-inflammatory COX-2 inhibitor celecoxib: the greater 
the inflammatory response, the better the outcome after treat-
ment with anti-inflammatory medication. However, a greater 
inflammatory response was associated also with better outcome 
after treatment with the antidepressant reboxetine alone. From a 
statistical point of view, it is relevant that two-thirds of the remit-
ters were in the celecoxib group; therefore, the effect in the whole 
group is primarily due to the effect in the celecoxib group.
The ratios between the metabolites are intriguing (1) the ratio 
between KYNA—a downstream metabolite of KYN—and KYN 
(KYNA/KYN), and (2) between QUIN—another downstream 
metabolite of KYN—and KYN (QUIN/KYN) were significantly 
lower in the overall group of remitters. Also, the remitters in 
the placebo group showed a higher KYNA/QUIN ratio. QUIN 
is an NMDA-R agonist and excitotoxic (29), and KYNA is an 
NMDA-R antagonist (26). Overall, the results also suggest that 
the lower the formation of downstream metabolites, especially 
the excitotoxic QUIN, the better the treatment outcome. From 
the findings concerning the lower KYNA/KYN and lower QUIN/
KYN ratios in remitters, it follows that the lower the degradation 
rate of KYN is to the downstream metabolites, the more KYN 
accumulates, and the higher the ratio is between KYN and TRP. A 
higher KYN/TRP ratio thus would mean less formation of down-
stream neurotoxic metabolites such as QUIN and subsequently 
would be associated with a better treatment outcome.
Our study shows that the KYN/TRP ratio may predict remission 
after antidepressant treatment with add-on anti-inflammatory 
medication using a COX-2 inhibitor, and this finding is also sig-
nificant for the overall patient group. Our study also highlighted 
the fact that an increased formation of the downstream neuroac-
tive KYN metabolites such as QUIN may negatively influence 
treatment outcome in depression. This finding is in line with the 
view that QUIN might be a pathogenetic factor in MD (30).
The increasing discussion of the role of inflammation and 
the increasing number of reports on beneficial effects of COX-2 
inhibitors in MD demand the identification not only of biomark-
ers to characterize the immunopathology of MD but also of 
immune markers for treatment response and remission. Another 
study of celecoxib add-on reported that decreased serum levels 
of the pro-inflammatory cytokine IL-6 predict the response to 
treatment (31). Our findings and the IL-6 report strengthen not 
only the view that inflammation and the TRP/KYN metabolites 
play a role in the pathogenesis of MD but also that markers of 
this system may be suitable to predict treatment remission with 
anti-inflammatory compounds.
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The present study also compared patients with MD to healthy 
individuals. We observed a higher QUIN/KYN ratio in the over-
all group of patients than in the healthy controls. This finding is 
in line with hypotheses previously proposed to explain the link 
between enhanced tryptophan degradation induced by activation 
of the inflammatory response system and subsequent enhanced 
formation of neurotoxic QUIN, thereby resulting in clinical 
symptoms such as depression (23, 32).
Our study has a major limitation: the overall sample size is 
rather small, thereby resulting in very small subgroups within 
each treatment group, e.g., of remitters and non-remitters. This 
small sample size has also some implications for statistics: no 
control for multiple comparisons has been performed. Therefore, 
the current results can only be interpreted with caution, and 
it is not yet possible to generalize them. Meaning, the present 
study should be seen as a pilot study for the identification of 
tryptophan metabolites as predictors for treatment remission 
and further studies with a larger sample size properly designed 
for a biomarker study should be performed. This future study 
could eventually divide patients into groups with high or low 
inflammatory markers. Nevertheless, our study can be seen as a 
first attempt on the way for a possible application of TRP/KYN 
metabolites to predict treatment outcome.
aUThOr cOnTriBUTiOns
DK, NM, A-MM, MR, VA, and MS planned the study, wrote the 
study protocol, and prepared the manuscript. A-MM, MS, and 
MR calculated the statistics. MS, CS, and A-MM performed the 
lab work. DK, SD, and AC recruited the patients and samples and 
helped for interpretation of the data.
FUnDing
Part of the work in this study was supported by EU FP7 col-
laborative research project Moodinflame (Grant No. 22963). The 
authors thank Jacquie Klesing, ELS, for editing assistance with 
the manuscript.
7Krause et al. Tryptophan Predicts Remission in Depression
Frontiers in Psychiatry | www.frontiersin.org February 2017 | Volume 8 | Article 16
25. Farmer BT II, Nicholas MM, Butterfield DA. The alteration of membrane 
proteins in human erythrocyte membranes induced by quinolinic acid, an 
endogenous neurotoxin. Correlation of effect with structure. Biochim Biophys 
Acta (1984) 778(2):260–8. doi:10.1016/0005-2736(84)90367-5 
26. Perkins MN, Stone TW. An iontophoretic investigation of the actions of con-
vulsant kynurenines and their interaction with the endogenous excitant quin-
olinic acid. Brain Res (1982) 247(1):184–7. doi:10.1016/0006-8993(82)91048-4 
27. Oades RD, Myint AM, Dauvermann MR, Schimmelmann BG, Schwarz MJ. 
Attention-deficit hyperactivity disorder (ADHD) and glial integrity: an explo-
ration of associations of cytokines and kynurenine metabolites with symptoms 
and attention. Behav Brain Funct (2010) 6:32. doi:10.1186/1744-9081-6-32
28. Morrison PF, Morishige GM, Beagles KE, Heyes MP. Quinolinic acid is extruded 
from the brain by a probenecid-sensitive carrier system: a quantitative analysis. 
J Neurochem (1999) 72(5):2135–44. doi:10.1046/j.1471-4159.1999.0722135.x 
29. Schwarcz R, Whetsell WO Jr, Mangano RM. Quinolinic acid: an endogenous 
metabolite that produces axon-sparing lesions in rat brain. Science (1983) 
219(4582):316–8. doi:10.1126/science.6849138 
30. Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, et  al. 
Severe depression is associated with increased microglial quinolinic acid 
in subregions of the anterior cingulate gyrus: evidence for an immune- 
modulated glutamatergic neurotransmission? J Neuroinflammation (2011) 
8:94. doi:10.1186/1742-2094-8-94 
31. Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect 
of celecoxib add-on treatment on symptoms and serum IL-6 concentrations 
in patients with major depressive disorder: randomized double-blind place-
bo-controlled study. J Affect Disord (2012) 141(2–3):308–14. doi:10.1016/j.
jad.2012.03.033 
32. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M. IDO 
and interferon-alpha-induced depressive symptoms: a shift in hypothesis from 
tryptophan depletion to neurotoxicity. Mol Psychiatry (2005) 10(6):538–44. 
doi:10.1038/sj.mp.4001600 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Krause, Myint, Schuett, Musil, Dehning, Cerovecki, Riedel, 
Arolt, Schwarz and Müller. This is an open­access article distributed under 
the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the orig­
inal author(s) or licensor are credited and that the original publication in 
this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these 
terms.
